A Growing Liver Disease Linked to Metabolic Imbalances, Inflammation
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world, affecting around 30% of Americans. It encompasses a spectrum of conditions, with non-alcoholic fatty liver (NAFL) being the milder form characterized by fat accumulation in the liver. Non-alcoholic steatohepatitis (NASH) is the more severe form, marked by inflammation and liver cell injury. NASH can progress to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) and is expected to surpass hepatitis C as the leading cause of liver transplantation within the next 5 to 15 years.
Obesity Fuels Rise in Nonalcoholic Fatty Liver Disease
The rise in obesity has led to increased metabolic diseases like insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease globally
NAFLD: Rising Global Health Issue Tied to Metabolic Dysfunction, Gut Microbiome, and Emerging Therapies
Non-alcoholic fatty liver disease (NAFLD) is characterized by ≥5% hepatic steatosis unrelated to alcohol or drug use, primarily driven by metabolic dysfunction, obesity, and type 2 diabetes.
MASLD: A Growing Global Health Concern Driven by Obesity, Diabetes, and Cardiovascular Risks
The terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been replaced by metabolic-dysfunction-associated steatotic liver disease (MASLD) to reduce stigmatization.
Rezdiffra and Noncirrhotic Non-alcoholic Steatohepatitis
The first US Food and Drug Administration-approved medication to treat noncirrhotic non-alcoholic steatohepatitis, otherwise known as NASH, is Rezdiffra (resmetirom).
Rising Obesity Fuels Nonalcoholic Fatty Liver Disease
The global rise in obesity has significantly increased the prevalence of non-alcoholic fatty liver disease (NAFLD), which can progress to severe conditions like nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
Nonalcoholic Fatty Liver Disease: The Impact of Significant Weight Loss
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease globally, and endoscopic sleeve gastroplasty (ESG) has emerged as a feasible and effective intervention for managing obesity.
